Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COR-1389
- Development stage
- Phase 1
- Lead developer
- Corteria Pharmaceuticals
- Modality
- Small Molecules, Peptides
- Administration
- Subcutaneous
01
Overview
COR-1389 is a very long-acting peptide agonist of the corticotropin-releasing hormone receptor 2 (CRF2/CRHR2), developed for once-monthly subcutaneous administration. It is being investigated primarily for the treatment of chronic diseases with high unmet medical need, including right heart failure, obesity (with comorbidities), and sarcopenia. Preclinical studies have shown that COR-1389 improves cardiopulmonary function and reduces right ventricular hypertrophy in models of right heart failure, lessens body weight by reducing fat mass while preserving muscle mass in obesity models, and ameliorates skeletal muscle wasting in sarcopenia models. The drug is currently in phase 1 clinical development[1][3][4][8].
02
Targets
CRHR2 (Corticotropin-releasing hormone receptor 2)
Beyond the preview
Go deeper on COR-1389.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COR-1389.